Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039 BOZEMAN, MT and VANCOUVER, BC — Microbion Corporation today announced that the US Patent… Read More
Survey examined healthcare professional (HCP) approaches to preventing organ damage – which impacts many people living with lupus within five years of diagnosis HCPs reported a need for earlier intervention… Read More
VANCOUVER, BC — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its… Read More
The Phase 4 EARNEST study met its primary efficacy endpoint of remission of chronic or recurrent pouchitis at Week 14, with 31% of participants receiving vedolizumab achieving remission versus 10%… Read More
Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of… Read More
